Results 271 to 280 of about 124,601 (306)
Some of the next articles are maybe not open access.
Everolimus in Diffuse Large B-Cell Lymphomas
Future Oncology, 2015Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell ...
Merli, Michele +4 more
openaire +4 more sources
Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma
Hematology/Oncology Clinics of North America, 2009Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features ...
Laurence, de Leval +1 more
openaire +2 more sources
Seminars in Radiation Oncology, 2007
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
openaire +2 more sources
NHL (diffuse large B-cell lymphoma).
BMJ clinical evidence, 2016Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003. Incidence rates show distinct geographical variation, with age-standardised incidence rates ranging from 17 per 100,000 in northern America to 4 per 100,000 in south-central Asia. NHL occurs more
Fiona, Kyle, Mark, Hill
openaire +3 more sources
Diffuse large B-cell lymphoma in the older
Critical Reviews in Oncology/Hematology, 2011The incidence of diffuse large B-cell lymphoma (DLCL) in the older is growing to the point of becoming a health priority in the next decades. Prognostic factors and the biology of the tumor are not very different between younger and older populations.
A, Gutiérrez +3 more
openaire +2 more sources
Treatment of diffuse large B-cell lymphomas
memo - Magazine of European Medical Oncology, 2009Diffuse large B-cell lymphoma represent 40% of all lymphoma. The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly. Evaluation of clinical risk factors (age, stage, LDH, ECOG performance status, number of extranodal involvement) at initial diagnosis are ...
B, Gleissner, C, Zwick, M, Pfreundschuh
openaire +2 more sources
Prognostic models for diffuse large b‐cell lymphoma
Hematological Oncology, 2000Prognosis of DLCL patients is variable and associated with well-defined risk factors. In the past decade several pretreatment variables have been incorporated into prognostic models to predict the death risk of individual patients. The International Prognostic Index (IPI), developed in an international consensus study, has been one of the most widely ...
A, Conconi +7 more
openaire +2 more sources
ALK‐positive diffuse large B‐cell lymphoma
Pediatric Blood & Cancer, 2005AbstractAnaplastic lymphoma kinase (ALK) positive diffuse large B‐cell lymphoma (DLBCL) is a rare subtype of non‐Hodgkins lymphoma. Five such cases have been described in children. We present a 9‐year‐old boy, in whom diagnosis of DLBCL has been established in addition to congenital multiple enchondromatosis. Immunohistopathological evaluation of tumor
Halina, Bubała +4 more
openaire +2 more sources
Pathogenesis of diffuse large B cell lymphoma
International Journal of Hematology, 2010Substantial additional insight has been obtained in the past decade regarding the pathogenesis of diffuse large B cell lymphoma (DLBCL). Distinct subtypes of DLBCL have been defined by gene expression profiling (GEP) and they differ not only in GE profiles but also in the pattern of genetic abnormalities.
openaire +2 more sources
Pancreatic Diffuse Large B-Cell Lymphoma
Journal of Gastrointestinal Surgery, 2023Cuiping Zhang, Keping Tan, Jun Li
openaire +2 more sources